SESSION TITLE: Respiratory Care
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM
PURPOSE: High flow nasal oxygen (HFNO) is an easy-to-use supportive therapy that has been demonstrated to be safe and effective in patients with acute hypoxic respiratory failure (AHRF) predominantly caused by community-acquired pneumonia (CAP) (N Engl J Med 2015; 372:2185), compared to face mask and noninvasive ventilation. HFNO decreases dead space, reduces airways resistance, and when humidified, is well tolerated. The objective of the study was to evaluate the outcome of patients with pneumonia (PNA) who used HFNO.